Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy

Documenti analoghi

• Differences in PD‐L1, PD‐L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study
  di: Ryosuke Sato, et al.
  Pubblicazione: (2025)
• A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  di: Mathias Fiedler, et al.
  Pubblicazione: (2026)
• Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes
  di: Kinnosuke Matsumoto, et al.
  Pubblicazione: (2026)
• Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum‐Based Therapy
  di: Tomomi Sanomachi, et al.
  Pubblicazione: (2025)
• Acral Melanoma Successfully Treated With Dacarbazine Following Anti‐ PD ‐1 Antibody Therapy: A Case Report and Literature Review
  di: Iemitsu Matsuda, et al.
  Pubblicazione: (2025)